Recurrent and/or metastatic thyroid cancer: Therapeutic options

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 7, 2002, Pages 939-947

  Karavitaki, Niki ^a   Vlassopoulou, Varvara ^a   Tzanela, Marinela ^a   Tzavara, Ioanna ^a   Thalassinos, Nicolaos ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Radioiodine; Recombinant human thyroid stimulating hormone; Retinoic acid; Thyroid carcinoma

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; METHOTREXATE; PACLITAXEL; PROTEIN P53; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; RETINOIC ACID; SODIUM IODIDE SYMPORTER; THYMIDINE KINASE; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN; THYROTROPIN;

ANAPLASTIC CARCINOMA; BONE MARROW SUPPRESSION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE THERAPY; HUMAN; LUNG FIBROSIS; MALE; METASTASIS; PROGNOSIS; RADIATION SICKNESS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; THYROID CANCER; THYROID FOLLICLE CELL; THYROIDITIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; MORTALITY; SURGERY; THYROID TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ANTINEOPLASTIC AGENTS; GENE THERAPY; HUMAN; IODINE RADIOISOTOPES; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; SURGERY; THYROID NEOPLASMS; THYROTROPIN; TRETINOIN; HUMANS;

EID: 0035987595     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.7.939     Document Type: Review

References (84)

1. Cancer incidence in five continents
2. Papillary and follicular thyroid carcinoma
3. The epidemiology of thyroid carcinoma
4. Epidemiology
5. Histological typing of thyroid tumours
6. Papillary lesions of the thyroid
7. Follicular lesions of the thyroid
8. Anaplastic thyroid carcinoma: Current diagnosis and treatment
9. An expanded view of risk-group definition in diffrentiated thyroid carcinoma
10. Natural history, treatment and course of papillary thyroid carcinoma
11. Predicting outcome of papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989
12. A comparison of different staging systems predictability of patient outcome: Thyroid carcinoma as an example
13. Long-term impact of initial surgery and medical therapy on papillary and follicular thyroid cancer
14. Thyroid gland
15. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients
16. Current approaches to primary therapy for papillary and follicular thyroid cancer
17. The results of various modalities of treatment of well differentiated thyroid carcinomas: A retrospective review of 1599 patients
18. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer
19. Thyrotropin suppression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry
20. AACE/AAES medical/surgical guidelines for clinical practice: Management of thyroid carcinoma
21. The effect of thyroid hormone on skeletal integrity
22. Reentrant atrioventricular nodal tachycardia induced by levothyroxine
23. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine
24. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma
25. Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR
26. An overview of the management of papillary and follicular thyroid carcinoma
27. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival
28. Surgical reintervention for differentiated thyroid cancer
29. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer
30. Side effects of 'rational dose' iodine-131 therapy for metastatic well-differentiated thyroid carcinoma
31. Lithium as a potential adjuvant to I131 therapy of metastatic, well differentiated thyroid carcinoma
32. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma
33. Detection of thyroid remnant/metastasis without stunning: An ongoing dilemma
34. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I
35. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels
36. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays
37. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan
38. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine
39. Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients
40. External radiotherapy in thyroid cancers
41. Long-term management of differentiated thyroid cancer
42. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy
43. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma
44. Differentiated thyroid carcinoma in children and adolescents: A 37-year experience in 85 patients
45. Differentiated thyroid cancer: Clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases
46. Different features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognostic variables
47. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma
48. Surgical treatment of distant metastases in differentiated thyroid cancer: Indication and results
49. The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma
50. Editorial: Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark?
51. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin
52. Thyroglobulin positive, RAI negative thyroid cancers: The role of conservative management
53. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic I-131 whole body scan: Comparison of patients treated with high I-131 activities versus untreated patients
54. Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma
55. Embolization for vertebral metastases of follicular thyroid carcinoma
56. Medical therapy for differentiated thyroid carcinoma
57. A randomized trial of doxorubicin plus cisplatin in patients with advanced thyroid carcinoma
58. I-131 therapy in differentiated thyroid carcinoma: M.D. Anderson hospital experience
59. Combined chemotherapy with bleomycin andriamycin and platinum in advanced thyroid cancer
60. Octreotide therapy in advanced thyroid cancer
61. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer
62. 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma
63. Waxman: Sialadenitis following I-131 therapy for thyroid carcinoma: Concise communication
64. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine
65. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine
66. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients
67. The long-term hazards of the treatment of thyroid cancer with radioiodine
68. Anaplastic thyroid carcinoma: Behavior, biology and therapeutic approaches
69. Uncommon types of thyroid cancer
70. Surgery in the treatment of thyroid cancer
71. Treatment of 37 patients with anaplastic carcinoma of the thyroid
72. Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase II trial using ninety-six-hour infusion
73. A multimodality therapeutic approach in anaplastic thyroid carcinoma: Study on 39 patients
74. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma
75. Differentiated thyroid cancer: A retrospective analysis of 832 cases from Greece
76. The use of recombinant thyrotropin in patients with thyroid cancer
77. Using recombinant human TSH in the management of well-differentiated thyroid cancer: Current strategies and future directions
78. Clinical use of recombinant human TSH in thyroid cancer patients
79. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH
80. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
81. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma
82. Retinoic acid redifferentiation therapy for thyroid cancer
83. Management of undifferentiated thyroid cancer
84. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo